

Date: 04.02.2019

To,

Senior General Manager
Listing Compliance
BSE Limited,
P.J. Tower, Dalal Street,
Fort, Mumbai – 400 001.

Dear Sir,

Sub: Application for revocation of suspension of M/s. Sangam Health Care Products Limited in trading of equity shares.

Ref: BSE email dated 01.02.2019

With reference to the subject cited, we enclose herewith the clarification required in respect of Un-audited Financial Results for the Quarter ended 30.09.2018. The revised results for the quarter ended 30.09.2018 is attached herewith.

We request the exchange to kind take the same on records and issue the in-principal approval for revocation of suspension of M/s. Sangam Health Care Products Limited in trading of equity shares.

Thanking you.

Yours faithfully,
For Sangam Health Care Products Limited


A. BalaGopal
Managing Director
DIN: 01712903



Encl: as above

CLARIFICATION

I, A. BalaGopal, Managing Director of M/s. Sangam Health Care Products Limited hereby clarifies that the difference between the un-audited financial results for the quarter ended 30.09.2018 sent on 06.11.2018 and 10.11.2018 is with regard to the format of statement of assets and liabilities. On the mail sent on 06.11.2018, the format was not as per IND AS and the mail sent on 10.11.2018, the format was as per IND AS. Hence, there are no changes in the figures.

In the view of above, we enclose herewith the revised un-audited results for the quarter ended 30.09.2018


For and on behalf of
Sangam Health Care Products Limited

Date: 04.02.2019
Place: Hyderabad

A. BalaGopal

A. BalaGopal
Managing Director
(DIN: 01712903)





LIMITED REVIEW REPORT

To.
The Board of Directors.
Sangam Health Care Products limited


We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, Secunderabad for the quarter and six months ended 30th September, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2004 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For K.R.Shekher & Co.,
Chartered Accountants
FRN : 010828S


Rajashekhar Kaparti
Partner

Membership No. 214810

Place: Hyderabad
Date: 06-11-2018

SANGAM HEALTH CARE PRODUCTS LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF ENDED SEP 30, 2018

Sl No.	Particular	Quarter ended			Half Year ended		Year ended
		30.09.2018 [Un-audited]	30.09.2017 [Un-audited]	30.06.2018 [Un-audited]	30.09.2018 [Un-audited]	30.09.2017 [Un-audited]	31.03.2018 [Audited]
1	Revenue from operations						
	a) net sales/ income from operations (net of excise duty)	601.05	511.16	504.11	1105.16	954.4	2,088.90
	b) Other operating income	-	0	-	0	0	0.67
	Total revenue from operations (net of excise duty)	601.05	511.16	504.11	1105.16	954.4	2,089.57
2	Other Income	0		0			1840.36
3	Total Income [1 + 2]	601.049	511.16	504.111	1105.16	954.4	3,929.93
4	Expenses:						
	Cost of material consumed	301.07	227.02	288.02	589.09	439.81	1177.56
	Purchase of Stock-in-trade	-	-	-	-	-	-
	Changes in inventories of Finished goods, work-in-progress & Stock in trade	14.9	70.27	-15	-0.1	31.39	327.66
	Employees benefit expenses	125.17	109.34	130.02	255.19	221.23	480.16
	Deprecation & amortization expenses	38.07	38.14	38.07	76.14	76.28	152.28
	Other expenses	176.43	210.52	172.45	348.88	431.62	899.24
	Total Expenses	655.64	655.29	613.56	1269.2	1200.33	3,036.92
5	Profit before exceptional and extraordinary items and tax (3 - 4)	-54.591	-144.13	-109.449	-164.04	-245.93	893.01
6	Exceptional items	-	0	0	0	-	-
7	Profit before and tax (5 - 6)	-54.591	-144.13	-109.449	-164.04	-245.93	893.01
8	Tax expense:						
	(1) Current tax	-	-	-	-	-	7.36
	(2) Deferred tax	-	-	-	-	-	148.28
9	Net Profit After Tax	-54.591	-144.13	-109.449	-164.04	-245.93	737.37
10	Other Comprehensive Income						
A	Items that will not be reclassified to statement of Profit & loss.						
	i) rereasurement benefits for the define benefit plans	-	-	-	-	-	-
	ii) equity instrumcments thourgh other comprehensive income	-	-	-	-	-	-
	iii) Defered tax relating to the above items	-	-	-	-	-	-
B	Net fair value loss on instrument in equity instruments thourgh OCI	-54.591	-144.13	-109.449	-164.04	245.93	737.37
	Total Other Comprehensive income /loss						
11	Total Other Comprehensive Income						
12	Paid-up Equity share capital	1486	1486	1486	1486	1486	1486

Abhishek



Abhishek

Date: 06.11.2018

To,
The Manager
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting under regulation 30 read Schedule III of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Ref: Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Tuesday, the 06th day of November, 2018 at 10.00 A.M. at the registered office of the Company the following were duly considered and approved by the Board:


1. Un-audited Financial Results for the quarter ended 30.09.2018
2. Limited Review Report for the quarter ended 30.09.2018.


The meeting concluded at 2.00 Noon

This is for the information and records of the Exchange, please.

Thanking you,

Yours faithfully,
For Sangam Health Care Products Limited


A. Bala Gopal
Managing Director
(DIN: 01702903)



13	Earnings per equity share:						
	(i) Basic						
	(ii) Diluted	-0.036	-0.096	-0.07	-0.11	-0.165	0.496

Notes:

- 1 The Unaudited results for the half year ended 30th September are in accordance with the Indian Accounting Standards (Ind AS) notified by the Ministry of Corporate Affairs which are applicable to the company for the accounting period beginning after 1st April, 2017
- 2 The Company operates in a single reportable operating segment. Hence there is no separate reportable segment as per Ind AS 108 "Operating Segment"
- 3 The Audit committee has reviewed these results and the board of directors have approved the above results at their meeting held on 06th November 2018
- 4 revenue from operation for period up to June, 30 2017 includes excise duty which is discontinued effective from 01 July, 2017 upon implementation of Goods & Service Tax (GST) in India. In accordance with Ind AS 18 Revenue recognition, GST is not included in revenue from operations.
- 5 The figures for corresponding previous period have been regrouped/reclassified wherever considered necessary to confirm the figure presented in the current period

Secunderbad

Date: 06.11.2018



For Sangam Healthcare Products Ltd

A. Bala Gopal
A. Bala Gopal

Managing Director



SANGAM HEALTHCARE PRODUCTS LTD
Statement of Assts and Liabilites

Particulars	As at 30.09.18 Un audited	As at 31.03.18 Audited
ASSETS		
Non-Current Assets		
Property, Plant & Equipments	1930	1993
Other intangible assets		
Financial Assets		
Advances	-	34
Total Non-current Assets	1930	2026
Current Assets		
Inventories	90	90
Financial Assets		
Investments	-	-
Trade Receivables	1	1
Cash and Cash Equivalents	3	17
Loans & Advances	108	84
Other Financial Assets	-	-
Total Current Assets	202	192
Total Assets	2132	2218
Equity & Liabilities		
Equity		
Equity Share Capital	1486	1486
Other Equity	-	-
Reserve & Surplus	-3023	-2859
Total Equity	-1537	-1373
Liabilities		
Non-Current Liabilities	1,455	1,466
Deffered Tax Liabilities Net	-	-
Total Non Current Liabilities	1,455	1,466
Current Liabilities		
Financial Liabilities	481	334
Trade Payables	480	526
Provisions	289	301
Other Current Liabilities	964	964
Total Current Liabilities	2,214	2,125
Total Liabilities	3,669	3,591
Total Equity & Liabilities	2,132	2,218

For Sangam Health Care Products Limited

A. Balagopal

Chairman and Managing Director

DIN: 01712903

Place: Hyderabad

Date: November 06, 2018

